Global /United States /Healthcare /Biotechnology /KLTO

Greenland Mines Ltd.

KLTO

• NASDAQ: KLTO • Delayed

0.4281USD -5.1%

As of 13 June 2026, Greenland Mines Ltd. has a market cap of $51.9M USD, ranking #30338 globally and #4440 in the United States. It ranks #2744 in the Healthcare sector, and #532 in the Biotechnology industry.

Global Rank

30338

Country Rank

4440

Sector Rank

2744

Industry Rank

532

Key Stats

Market Cap

$51.9MUSD

Enterprise Value

$47.5MUSD

Net Income (TTM)

-$10.55MUSD

PB Ratio

3.5

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Biotechnology

CEO

Joseph Sinkule open_in_new

Employees

Website

greenlandmines.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-5.1%	8.1%	47%	48%	-17%	50%	140%	-96%	-95%

News

KLTO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	KLTO Klotho Neurosciences Inc ISIN: US49876K1034 Shares Out.: Shares Outstanding: 73.537M¹ Shares Float: 65.792M² TV: TradingView: NASDAQ: KLTO SA: Stock Analysis: NASDAQ: KLTO YF: Yahoo Finance: KLTO GF: Google Finance: NASDAQ: KLTO NQ: NASDAQ: KLTO BA: Barron's: KLTO MS: Morningstar: XNAS: KLTO	0.4281 USD	TV: TradingView: NASDAQ: KLTO SA: Stock Analysis: NASDAQ: KLTO YF: Yahoo Finance: KLTO GF: Google Finance: NASDAQ: KLTO NQ: NASDAQ: KLTO BA: Barron's: KLTO MS: Morningstar: XNAS: KLTO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Greenland Mines Ltd.

Greenland Mines Ltd operates as a natural resources company. It focuses on the exploration and development of Skaergaard Project in Southeast Greenland. The company is also involved in the development of KLTO-202, a cell and gene therapy for amyotrophic lateral sclerosis. The company was formerly known as Klotho Neurosciences, Inc. and changed its name to Greenland Mines Ltd in March 2026. Greenland Mines Ltd is based in Charlotte, North Carolina.

Similar Companies

Industry: Biotechnology (United States)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 351K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 308K%	19.0	United States
Natera, Inc. NASDAQ: NTRA	$27.6B 53K%	-	United States
IQVIA Holdings Inc. NYSE: IQV	$26.3B 51K%	20.0	United States
United Therapeutics Corp. NASDAQ: UTHR	$25.03B 48K%	20.4	United States
Moderna, Inc. NASDAQ: MRNA	$18.13B 35K%	-	United States

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
argenx SE EBR: ARGX	$47.84B 41.39B EUR 92K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 86K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 82K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 81K%	37.2	Switzerland
Celltrion, Inc. KRX: 068270	$28.11B 42.76T KRW 54K%	43.8	South Korea
BioNTech SE NASDAQ: BNTX	$25.69B 49K%	-	Germany

chevron_leftBack